ADRx Inc

ADRx Inc. is a preclinical biotechnology company headquartered in Thousand Oaks, California. The company is privately held and currently employs 4 people. ADRx focuses on developing small molecule disaggregators and inhibitors for misfolded proteins implicated in neurodegenerative diseases. Their proprietary structure-based technology allows them to target proteins that were previously considered "undruggable." The company's current pipeline includes programs targeting tau, TDP-43, and alpha-synuclein. A key differentiator for ADRx is its unique approach to drug development, leveraging structure-based technology to address challenging therapeutic targets. This innovative approach holds promise for creating novel treatments for debilitating neurodegenerative diseases. For more information on ADRx Inc. and its research, visit their website at adrxpharma.com.